Return to ads
All categories


Posted by
Posting ads for 49 years
�Wall Street News Alert: Morning Watch: Trade Alert: ANPI, PPHMThu.

May 28, 2009; Posted: 09:09 AM Are you looking to increase your ETF knowledge? Miramar, FLA., May 28, 2009 (M2 PRESSWIRE via COMTEX) -- PPHM | Quote | Chart | News | PowerRating -- Wall Street News Alert is issuing its "Daily Market Movers Report" for Thursday morning.

It includes: Angiotech Pharmaceuticals, Inc.

(NASDAQ: ANPI | Quote | Chart | News | PowerRating) and Peregrine Pharmaceuticals, Inc.


For more information, please visit

Angiotech Pharmaceuticals, Inc.


Angiotech Pharmaceuticals, Inc.

(NASDAQ: ANPI | Quote | Chart | News | PowerRating) closed yesterday up 45.52% on over 13.4 million shares traded.

To view the complete release, please visit: May 27, 2009 - Yesterday, Angiotech Pharmaceuticals, Inc announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S.

Food and Drug Administration (FDA) to market its TAXUS Liberte Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels.

It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS Express Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S.

The Company plans to begin a full U.S.

launch of TAXUS Liberte Atom next month.

"The rapid adoption of the TAXUS Express Atom Stent has confirmed the need for this type of stenting option in the treatment of small-vessel coronary artery disease," said Mark Turco, M.D., F.A.C.C., F.S.C.A.I., Director of the Center for Cardiac and Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland.

"The TAXUS Liberte Atom Stent provides clear design and deliverability advantages.

Additionally, in the TAXUS Atlas Small Vessel clinical trial, the TAXUS Liberte Atom Stent yielded a two-year target lesion revascularization rate that was 60 percent less than the TAXUS Express Atom Stent.

I am pleased to be able to offer this option to my patients." About the company: Angiotech Pharmaceuticals, Inc.

is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees.

Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.

Peregrine Pharmaceuticals, Inc.

(NASDAQ: PPHM) Peregrine Pharmaceuticals, Inc.

(NASDAQ: PPHM | Quote | Chart | News | PowerRating) closed yesterday up 15.38% on over 3.5 million shares traded.

To view the complete release, please visit: May 28, 2009 - Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today provided an update on progress in the company's clinical program for Cotara, a targeted monoclonal antibody-based therapy being tested in a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer.

The company also reported that patient enrollment in the final cohort of a second Cotara GBM trial, a dose confirmation and dosimetry study, is nearing completion and that interim data from this trial has been accepted for an oral presentation at the Society of Nuclear Medicine Annual Meeting to be held June 13-18, 2009.

More than 65 patients with recurrent GBM have received Cotara in the current and previous clinical studies.

Localization and accumulation of the drug to the tumor have been excellent and longer-term survivors (greater than one year from the time of Cotara treatment) have been observed in all of the trials, with some GBM patients from early clinical studies now alive more than 8.5 years after treatment with Cotara.

Expected survival for patients with GBM is approximately six months from time of disease recurrence.

About the company: Peregrine Pharmaceuticals, Inc.

is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections.

The company is pursuing three separate clinical programs in cancer and hepatitis C virus (HCV) infection with its lead product candidates bavituximab and Cotara.

Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc.

(, which provides development and bio-manufacturing services for both Peregrine and outside customers.

You can also receive our free mobile stock alerts formatted especially for your cell phone, text the word "press" in the subject line to 68494.

*** This free service can be discontinued at any time by replying to any one of the alerts with the word "stop".

WSNA's email alert service is free to those investors who sign up on the WSNA home page.

The alert service is designed to notify investors of often overlooked stocks.

Subscribers are introduced to Special Situation companies that have the potential of showing increased activity.

The Wall Street News Alert home page has experienced over 100 million hits.

To subscribe to this free service, visit the Wall Street News Alert home page at and select the "join now" button.

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF).

WSCF also maintains a contractual, working relationship with Stock Market Alerts LLC and its' Wall Street Enews brand.

WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security.

WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities.

An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved.

The material in this release is intended to be strictly informational.

The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release.

All statements and expressions are the sole opinion of WSCF and are subject to change without notice.

Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research.

The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.

WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release.

The release may contain technical inaccuracies or typographical errors.

It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies.

Investment in the securities of the companies' discussed in this release is highly speculative and carries a high degree of risk.

WSCF is not liable for any investment decisions by its readers or subscribers.

Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks WSCF has not been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release.

However, WSCF may receive compensation for future services.

Any additional compensation will be disclosed at such time that WSCF is aware of a clients desire to extend the original services.

WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release.

WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF.

WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company.

In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected".

You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

CONTACT: Wall Street News Alert e-mail: [email protected] WWW: ((M2 Communications disclaims all liability for information provided within M2 PressWIRE.

Data supplied by named party/parties.

Further information on M2 PressWIRE can be obtained at on the world wide web.

Inquiries to [email protected]

For full details for ANPI click here.

���� More News:�� Market Updates | Stock Alerts | All Trading News | Stock IndexEmailPrintArchivesFeedbackEmail Article LinkClose XRecipients email addressYour nameYour email Add a note (optional)
Reply to this ad
Recently viewed ads
Saved ads
Please log in to browse your saved adverts or sign up if you don't have an account yet.
Popular Stuff